Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Completed
Seagen Inc.
Phase 1
2006-11-01
Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in
patients with relapsed/refractory CD30-positive hematologic malignancies. This is a
single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK,
immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory
CD30-positive hematologic malignancies.
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Completed
Seattle Genetics, Inc.
Phase 1
2006-11-01
Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in
patients with relapsed/refractory CD30-positive hematologic malignancies. This is a
single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK,
immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory
CD30-positive hematologic malignancies.
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Terminated
Seagen Inc.
Phase 1
2008-03-01
This study will examine the safety profile of SGN-35 alone and in combination with
gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of
patients.
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Terminated
Seattle Genetics, Inc.
Phase 1
2008-03-01
This study will examine the safety profile of SGN-35 alone and in combination with
gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of
patients.
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Completed
Millennium Pharmaceuticals, Inc.
Phase 2
2009-02-01
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the
efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with
relapsed or refractory Hodgkin lymphoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.